Stockscreener 앱 받기
16.68
32.32%
-7.775
전일 마감가:
$24.45
열려 있는:
$15.24
하루 거래량:
20.28M
Relative Volume:
2.76
시가총액:
$1.63B
수익:
$2.48B
순이익/손실:
$-57.96M
주가수익비율:
-21.98
EPS:
-0.7585
순현금흐름:
$-453.97M
1주 성능:
-31.67%
1개월 성능:
-26.91%
6개월 성능:
-73.94%
1년 성능:
-86.55%
1일 변동 폭
$15.08
$17.75
1주일 범위
$15.08
$24.55
52주 변동 폭
$10.41
$138.81
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
SRPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
16.70 | 2.56B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.90 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
630.19 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
425.06 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.21 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.00 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-22 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 개시 | Bernstein | Mkt Perform |
| 2025-07-29 | 재확인 | H.C. Wainwright | Sell |
| 2025-07-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-07-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 개시 | Citigroup | Sell |
| 2025-07-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-07-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-21 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-07-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-07-21 | 다운그레이드 | Needham | Hold → Underperform |
| 2025-07-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-18 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-06-17 | 개시 | Wolfe Research | Peer Perform |
| 2025-06-16 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | 다운그레이드 | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
Baird Maintains Neutral Rating, Lowers Price Target on SRPT | SRPT Stock News - GuruFocus
SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure - Zacks Investment Research
Scandal and controversy take toll on FDA credibility - statnews.com
Sarepta (SRPT) Shares Plummet Over 33% - GuruFocus
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance - inkl
Sarepta (SRPT) Faces Stock Plunge Amid Clinical Trial Setbacks - GuruFocus
Sarepta stock plummets as confirmatory Duchenne trial fails - The Business Journals
Top Stock Movers Now: Palantir, Sarepta Therapeutics, Denny's, and More - MSN
Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It - Benzinga
Sarepta Therapeutics Stock Tumbles After Trial Data - Schaeffer's Investment Research
Palantir, Uber, Sarepta, Tesla, Norwegian Cruise Line, Hertz, AMD, and More Movers - Barron's
Sarepta (SRPT) Stock Plummets Over 30% - GuruFocus
Sarepta shares tumble on trial failure, weak Elevidys outlook - Reuters
Sarepta Plunges On Study Failures, Gene Therapy Outlook - Investor's Business Daily
Stocks to Watch Tuesday: Palantir, Sarepta, Tesla -- WSJ - 富途牛牛
Sarepta Stock Dives 35% After Earnings Report. Why Shares Are Crashing. - Barron's
Sarepta Therapeutics (SRPT) Stock: Clinical Failure Triggers Massive Selloff - parameter.io
Sarepta Therapeutics (SRPT) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo! Finance UK
Sarepta Duchenne drugs come up short in confirmatory test - BioPharma Dive
Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat (NASDAQ:SRPT) - Seeking Alpha
Sarepta’s DMD Exon-Skippers Fail Confirmatory Study, Stock Craters - BioSpace
Stocks making the biggest moves premarket: Uber, Sarepta, Palantir, Norwegian Cruise and more - CNBC
Sarepta shares slide as DMD treatment woes pile up - pharmaphorum
Needham Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating - 富途牛牛
Sarepta Says Older Muscle Disease Drugs Failed Confirmatory Trial - Bloomberg
Sarepta Earnings Beat Expectations. Why the Stock Is Down 40%. - Barron's
Sarepta slumps after approved muscle disorder drugs fail confirmatory trial - TradingView
Palantir, Sarepta, Tesla, Uber, Pfizer, Norwegian Cruise Line, Amazon, AMD, and More Movers - Barron's
Morning Market Movers: DENN, SRPT, JELD, ICHR See Big Swings - RTTNews
Sell Rating for Sarepta Therapeutics Amid ESSENCE Study Disappointment and Reimbursement Concerns - TipRanks
Sarepta slumps as trial failure deepens woes for drugmaker - Yahoo! Finance Canada
Two of Sarepta’s DMD drugs fail to meet primary endpoint in confirmatory trial - Yahoo Finance
Multi asset correlation models including Sarepta Therapeutics Inc.Weekly Stock Analysis & Community Consensus Picks - newser.com
Relative strength of Sarepta Therapeutics Inc. in sector analysisPortfolio Return Report & Long-Term Growth Plans - newser.com
Sarepta Stock Tumbles 40%. Why the Biotech’s Shares Are Sinking. - MSN
Dow Futures Edge Lower On Pullback Fears: PLTR, SRPT, TSLA, AMD Among Stocks To Watch - Stocktwits
Baird lowers Sarepta Therapeutics stock price target to $15 on ESSENCE trial failure - Investing.com Nigeria
Analyzing drawdowns of Sarepta Therapeutics Inc. with statistical toolsTrade Analysis Report & Risk Controlled Daily Trade Plans - newser.com
Palantir, Sarepta, Tesla, Amazon, AMD, Pfizer, and More Stock Market Movers - Barron's
Palantir, Sarepta, Amazon, AMD, Pfizer, and More Stock Market Movers - Barron's
Sarepta Therapeutics (SRPT) Stock Crashes as Nine-Year Trial Ends in Disappointment - CoinCentral
Biggest stock movers Tuesday: PLTR, SRPT, and more (NASDAQ:PLTR) - Seeking Alpha
Sarepta slumps as gene therapy setback adds to drug pipeline woes - Yahoo Finance
Pinnacle Associates Ltd. Has $997,000 Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Stocks to Watch Tuesday: Palantir, Sarepta, Tesla - The Wall Street Journal
Is Sarepta Therapeutics Inc. stock supported by strong cash flowsJuly 2025 Levels & Risk Managed Investment Signals - newser.com
Will Sarepta Therapeutics Inc. (AB3A) stock test record highs in 2025July 2025 Gainers & Consistent Income Trade Ideas - newser.com
Will Sarepta Therapeutics Inc. stock benefit from sector rotationQuarterly Market Review & Technical Confirmation Alerts - newser.com
Sarepta Therapeutics Swings to Q3 Adjusted Loss, Revenue Falls; Shares Down Pre-Bell - MarketScreener
What technical charts say about Sarepta Therapeutics Inc. stockJuly 2025 Macro Moves & High Accuracy Investment Signals - newser.com
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.13%
0.49%
자본화:
|
볼륨(24시간):